Monte Rosa Therapeutics outlines 2023 milestones; MRT-2359 Fast Track designation from FDA

Monte Rosa Therapeutics, Inc.

MRT-2359 granted FDA Fast Track for previously treated metastatic NSCLC with L-MYC or N-MYC expression.
Initial Phase 1 data from ongoing Phase 1/2 trial of MRT-2359 expected in H2 2023.
Company anticipates nomination of multiple development candidates in 2023 across oncology, autoimmune, and inflammatory indications.
Presentation at J.P. Morgan Healthcare Conference on Jan 11, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.